MA45165A - Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées - Google Patents

Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées

Info

Publication number
MA45165A
MA45165A MA045165A MA45165A MA45165A MA 45165 A MA45165 A MA 45165A MA 045165 A MA045165 A MA 045165A MA 45165 A MA45165 A MA 45165A MA 45165 A MA45165 A MA 45165A
Authority
MA
Morocco
Prior art keywords
influenzatigenic
polypeptides
modified
immunogenic compositions
associated immunogenic
Prior art date
Application number
MA045165A
Other languages
English (en)
Inventor
Eliud Oloo
Tod Strugnell
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MA45165A publication Critical patent/MA45165A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16062—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA045165A 2016-06-02 2017-06-02 Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées MA45165A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662344862P 2016-06-02 2016-06-02

Publications (1)

Publication Number Publication Date
MA45165A true MA45165A (fr) 2019-04-10

Family

ID=59227901

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045165A MA45165A (fr) 2016-06-02 2017-06-02 Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées

Country Status (6)

Country Link
US (2) US10844097B2 (fr)
EP (1) EP3464328A1 (fr)
AU (2) AU2017272344B2 (fr)
CA (1) CA3026096A1 (fr)
MA (1) MA45165A (fr)
WO (1) WO2017210599A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023018817A1 (fr) 2021-08-11 2023-02-16 Sanofi Pasteur Inc. Neuraminidase grippale tronquée et procédés d'utilisation de cette dernière
CN116284432A (zh) * 2022-09-09 2023-06-23 中山大学·深圳 一种乙型流感病毒重组蛋白疫苗及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (fr) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Oligonucleotides immunomodulateurs
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
JP2001513776A (ja) 1997-02-28 2001-09-04 ユニバーシティ オブ アイオワ リサーチ ファウンデーション ＬＰＳ関連障害の処置における非メチル化ＣｐＧジヌクレオチドを含む核酸の使用
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU7690898A (en) 1997-05-20 1998-12-11 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
JP2002510644A (ja) 1998-04-03 2002-04-09 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
IL152426A (en) 2000-04-28 2011-07-31 St Jude Childrens Res Hospital A DNA transfection system to form an infectious negative-strand RNA virus
CA2551489C (fr) 2003-12-23 2013-09-03 Gregory Duke Systeme a plasmides multiples pour la production du virus de la grippe
AU2007345682B2 (en) 2006-07-27 2013-07-18 Ligocyte Pharmaceuticals, Inc. Chimeric virus-like particles
US8980281B2 (en) * 2006-09-05 2015-03-17 Academia Sinica High-yield transgenic mammalian expression system for generating virus-like particles
US20110059130A1 (en) 2007-08-20 2011-03-10 Fraunhofer Usa, Inc. Prophylactic and therapeutic influenza vaccines, antigens, compositions and methods
PT2610345E (pt) 2007-11-27 2016-01-11 Medicago Inc Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina
EA034733B1 (ru) 2008-01-21 2020-03-13 Медикаго Инк. Нуклеиновая кислота для увеличенной экспрессии гемагглютинина вируса гриппа в растении и ее применение
EP2758038B1 (fr) * 2011-09-23 2018-05-30 The United States of America, as represented by The Secretary, Department of Health & Human Services Nouveaux vaccins à base de protéine hémagglutinine de la grippe
KR20140127827A (ko) * 2012-02-07 2014-11-04 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 H3n2, h2n2, 및 b 인플루엔자 바이러스에 대한 계산적으로 최적화된 넓게 반응하는 항원
RU2639551C2 (ru) * 2012-03-30 2017-12-21 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
US8932598B2 (en) * 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
US20140286981A1 (en) * 2013-03-14 2014-09-25 Wisconsin Alumni Research Foundation Broadly reactive mosaic peptide for influenza vaccine
US20170121373A1 (en) * 2014-05-30 2017-05-04 Sanofi Pasteur Inc. Expression and conformational analysis of engineered influenza hemagglutinin
US10548965B2 (en) * 2014-12-19 2020-02-04 Oregon Health & Science University Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
CA2987939A1 (fr) 2015-06-02 2016-12-08 Sanofi Pasteur Inc. Polypeptides antigeniques de la grippe modifies et compositions immunogenes correspondantes
CN108290932A (zh) * 2015-06-09 2018-07-17 圣诺菲·帕斯图尔公司 优化编码工程改造的流感蛋白的核苷酸序列的方法

Also Published As

Publication number Publication date
AU2017272344A1 (en) 2018-12-13
EP3464328A1 (fr) 2019-04-10
WO2017210599A1 (fr) 2017-12-07
AU2022203625A1 (en) 2022-06-16
US20190161519A1 (en) 2019-05-30
US20210147488A1 (en) 2021-05-20
US10844097B2 (en) 2020-11-24
CA3026096A1 (fr) 2017-12-07
AU2022203625B2 (en) 2024-04-04
AU2017272344B2 (en) 2022-03-03

Similar Documents

Publication Publication Date Title
MA47515A (fr) Compositions immunogènes très puissantes
DK3592393T3 (da) Frigørbare konjugater
DK3529248T3 (da) Farmaceutiske sammensætninger
MA50755A (fr) Conjugués anticorps-médicaments mult-médicaments
DK3697376T3 (da) Sammensætning
DK3412302T3 (da) Modificerede fgf-21-polypeptider og anvendelser deraf
DK3096785T3 (da) Immunogene sammensætninger omfattende konjugerede kapsel-saccharid-antigener og anvendelser deraf
DK3137114T3 (da) Anti-PTK7-antistof-lægemiddelkonjugater
MA50657A (fr) Formulations de niraparib
BR112018000054A2 (pt) composições farmacêuticas liofilizadas
DK3464456T3 (da) Hængslet komponent omfattende polyethylensammensætning
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3528902T3 (da) Ringegelsammensætning
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3426728T3 (da) Termoplastisk sammensætning
DK3258174T3 (da) Ovn
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
DK3288640T3 (da) Tørshampoosammensætning
DK3544634T3 (da) MET-antistof-lægemiddelkonjugater
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
ES2663220A8 (es) Composicion panificable exenta de gluten
BR112018000396A2 (pt) composições de nicergolina de liberação modificada
MA50068A (fr) Formulations de copanlisib